envudeucitinib
envudeucitinib: developed by 1 company · 6 clinical trials tracked.
envudeucitinib evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
How could envudeucitinib → ALMS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| ALUMIS INC. (ALMS) Renal Impairment; Healthy Volunteer | Phase 1 |
| ALUMIS INC. (ALMS) SLE; Plaque Psoriasis; Hepatic Impairment | Phase 1 |
Clinical Trials (6)
A Phase 1, Open Label, Single Dose Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of ESK001
Primary endpoint: Maximum observed plasma concentration (Cmax)
A Phase 1, Open-label, Single-dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of ESK-001
Primary endpoint: Maximum observed plasma concentration (Cmax)
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
Primary endpoint: To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)
Primary endpoint: To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients With Systemic Lupus Erythematosus
Primary endpoint: To compare the effect on disease activity measured by the proportion of patients achieving British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at Week 48 between doses of ESK-001 and placebo
A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis
Primary endpoint: To assess the safety and tolerability of long-term ESK-001 treatment
Frequently asked questions
Who is developing envudeucitinib?
envudeucitinib is being developed by ALUMIS INC..
How many clinical trials involve envudeucitinib?
BioSniper tracks 6 clinical trials involving envudeucitinib.